Genmab Submits Protocol Amendment For Ofatumumab Phase 3 Head-to-head StudyRTT NewsAccording to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherapy in relapsed or r…
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCLMarketWatch (press release)According to the amended protocol all patients recruited in the study which investigates ofatumumab plus chemotherapy versus rituximab plus chemotherap…
Roche's Avastin is top requested medicine in UK's cancer drugs fundPMLiVEOther drugs that received a high number of applications under the Cancer Drugs Fund included GSK's Tyverb (lapatinib), Roche's MabThera (rituximab) and Novartis…
Man survives with brother's kidney despite mismatchTimes of IndiaWe administered the patient with a drug called Rituximab to reduce antibodies in his blood. Pyaare's blood type is O while his brother's is type B," said Dr Sanjiv Jasuja…
The Oncology ReportFake and Gray Market Drugs Vex US OncologistsThe Oncology ReportThe agency named Faslodex (fulvestrant), Neupogen (filgrastim), Rituxan (rituximab) and Herceptin (trastuzumab) – but not Avastin – in the warning. Subsequently, the…
Chinese Monoclonal Antibody Industry 2012 Research ReportSBWire (press release)Roche is the biggest winner in monoclonal antibody market, and the products with the largest market share; Rituximab and Trastuzumab, are from Roche Group. Merck and Novarti…
HemOncTodayLow-dose rituximab plus steroids demonstrated safety, efficacy in autoimmune …HemOncTodayThe combination of low-dose rituximab and steroids was linked to overall response rates of more than 80% in a cohort of patients with autoimmune hemol…
Chronic Lymphocytic Leukemia – Aggressive Drug Combo Restores Quality Of LifeMedical News TodayFC in combination with rituximab, a monoclonal antibody drug, has proven to be the most effective therapy for extending life and has become the standard trea…
OncLiveNoteworthy Research Spans Range of MalignanciesOncLiveRituximab antibodies (turquoise) bind to the CD20 cell-surface markers on B-cells. A second paper reported the results of a most interesting phase III randomized trial that the Eastern Cooper…
IMARC Group Releases the Most Comprehensive Study on the US Follow-on …PharmiWeb.com (press release)… Interferon Beta-1A (Rebif), Interferon Beta-1B (Betaferon), Bevacizumab (Avastin), Trastuzumab (Herceptin), Rituximab (Mabthera/Rituxan), Cetuxima…